Skip to main content

Table 1 Associations of DC-SCRIPT with clinicopathological and biological factors

From: Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study

Characteristic

Number of patients

Percentagea

DC-SCRIPTb (reference-normalized), × 102

All patients

1,505

100%

0.69

0.73

Age, years

    

   ≤ 40

192

13%

0.69

0.72

   41-55

561

37%

0.70

0.74

   56-70

498

33%

0.70

0.77

   >70

254

17%

0.64

0.64

   

P = 0.15c

 

Menopausal status

    

   Premenopausal

637

42%

0.72

0.74

   Postmenopausal

868

58%

0.66

0.70

   

P = 0.06d

 

Grade

    

   Poor

818

54%

0.64

0.74

   Unknown

452

30%

0.71

0.68

   Moderate and good

235

16%

0.80

0.70

   

P = 0.001e

 

Tumor size

    

   pT1, ≤ 2 cm

517

34%

0.81

0.84

   >2 cm

988

66%

0.63

0.64

   

P < 0.001d

 

Lymph nodes involved

    

   No

837

56%

0.69

0.73

   Yes

668

44%

0.68

0.75

   

P = 0.64d

 

ESR1 mRNA statusf

    

   Positive, ≥0.2

1,176

78%

0.71

0.73

   Negative, < 0.2

329

22%

0.61

0.66

   

P = 0.004c

 

PGR mRNA statusf

    

   Positive, ≥0.1

949

63%

0.72

0.74

   Negative, < 0.1

556

37%

0.61

0.66

   

P < 0.001c

 

ESR2 mRNA statusf

    

   Dichotomized high, ≥0.005

741

49%

0.89

0.95

   Dichotomized low, < 0.005

742

49%

0.54

0.49

   

P < 0.001c

 

Invasive tumor cell contentg

    

   ≥70%

719

48%

0.57

0.51

   < 70%

786

52%

0.85

0.91

   

P < 0.001d

 

Histological type

    

   DCIS + IDC

194

13%

0.82

0.89

   ILC

135

9%

0.81

0.94

   IDC

810

54%

0.66

0.69

   Mucinous

40

3%

0.56

0.65

   Medullary

31

2%

0.69

1.18

   

P = 0.012e

 

Intrinsic breast cancer subtypeh

308

   

   Normal-like

22

7%

1.43

1.19

   ERBB2+

63

20%

0.75

0.68

   Luminal A

76

25%

0.78

0.89

   Luminal B

65

21%

0.56

0.36

   Basal

82

27%

0.48

0.48

   

P < 0.001e

 
  1. aOwing to missing cases, numbers do not always add up to 100%. bMedian level and p50 inter-quartile after normalization on the reference gene set. cP for Spearman rank correlation test. dP for Mann-Whitney U test. eP for Kruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate. fWith quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005 (mRNA levels relative to reference gene set). gDichotomized at the median level of 70% invasive tumor cells. hIntrinsic breast cancer subtypes assigned from Affymetrix microarray by hierarchical clustering of 308 lymph-node negative disease patients who did not receive systemic adjuvant treatment. DCIS, ductal carcinoma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.